How Will the Market React to AcelRx Pharmaceuticals Inc (ACRX) Stock Getting a Bullish Rating

Friday, December 23, 2022 01:21 PM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to AcelRx Pharmaceuticals Inc (ACRX) Stock Getting a Bullish Rating

AcelRx Pharmaceuticals Inc (ACRX) stock is down 7.53% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

AcelRx Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ACRX!

See Full ACRX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ACRX Stock Today?

AcelRx Pharmaceuticals Inc (ACRX) stock has fallen -3.29% while the S&P 500 has risen 0.41% as of 1:20 PM on Friday, Dec 23. ACRX is down -$0.08 from the previous closing price of $2.28 on volume of 56,495 shares. Over the past year the S&P 500 is down -18.28% while ACRX is down -80.44%. ACRX earned $6.21 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 0.35.

More About AcelRx Pharmaceuticals Inc

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States. Click Here to get the full Stock Report for AcelRx Pharmaceuticals Inc stock.